MECP2 and Rett syndrome: It is known that specific mutations in MECP2 confer different severity in RTT [17,20]; therefore, in addition to the relationship between plasma neuroprostane levels and MECP2 mutation (Figure 2, Figure 3 and Figure 4), the distribution of circulating neuroprostane molecules as a function of clinical severity was evaluated.